Voyager Therapeutics

Voyager Therapeutics, a Cambridge‑based biotech, develops gene and antibody therapies for neurodegenerative disorders, led by a Phase 1b anti‑tau drug for Alzheimer’s. It partners with major pharma and focuses on high‑impact markets.

Headquarters: United States (USA)

Voyager Therapeutics Logo
Company Profile
  • Employees: 172
  • HQ: Lexington
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
VYGR Voyager Therapeutics
Cap: 0.2B
EQUITY NMS USD US92915B1061 Active
📈
Home Login